@article{ab34283b3baa4cba976bccaa9255a4df,
title = "Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: Different methodologies-Conflicting results?",
keywords = "Autoantibodies, multiple sclerosis (MS), pathology, proteomics",
author = "Bernhard Hemmer",
note = "Funding Information: B. Hemmer has served on scientific advisory boards for Roche, Novartis, Bayer Schering, Merck Serono, Biogen Idec, GSK, Chugai Pharmaceuticals, Micromet and Genzyme Corporation; serves on the international advisory board of Archives of Neurology and Experimental Neurology; has received speaker honoraria from Bayer Schering, Novartis, Biogen Idec, Merck Serono, Roche, and Teva Pharmaceutical Industries Ltd; and has received research support from Biogen Idec, Bayer Schering, Merck Serono, Five prime, Metanomics, Chugai Pharmaceuticals and Novartis. He has been filed a patent for the detection of antibodies and T cells against KIR4.1 in a subpopulation of MS patients. Funding Information: BH was supported by grants from the German Ministry for Education and Research (BMBF, “German Competence Network Multiple Sclerosis” (KKNMS) 01GI0917) and the Munich Biomed Cluster M4.",
year = "2015",
month = apr,
day = "1",
doi = "10.1177/1352458514564493",
language = "English",
volume = "21",
pages = "537--539",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "5",
}